Future BMS CEO Boerner Pleas For Patience As New Products Build Momentum

Earnings Report Was Preempted By C-Suite Change-Up

Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.

Achievement of each set goal
With many new drugs launched, now BMS must meet several big sales targets • Source: Shutterstock

Christopher Boerner will take over the CEO role at Bristol Myers Squibb Company on 1 November when Giovanni Caforio retires. And as he has done for the last several BMS earnings calls as chief commercialization officer, Boerner spent the company’s first quarter 2023 call on 27 April discussing new launches that will drive revenue growth as current blockbusters lose exclusivity. In some high-profile products’ cases, he pleaded for patience as those assets establish their commercial footing.

[Sidebar#SC148278]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Executives On The Move

More from Leadership